Current concepts in pharmacologic management of chronic obstructive pulmonary disease

Seminars in Respiratory and Critical Care Medicine

Volumn 20, Issue 4, 1999, Pages 279-288

  Boueri, Fernanda M V ^a   Make, Barry J ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Antibiotics; Anticholinergic bronchodilators; Beta agonist bronchodilators; Corticosteroids

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAMASE INHIBITOR; BRONCHODILATING AGENT; BUDESONIDE; CEFUROXIME; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; MACROLIDE; METHYLXANTHINE; OFLOXACIN; OXITROPIUM BROMIDE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; SALMETEROL; STEROID; TETRACYCLINE; THEOPHYLLINE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; IRRITABILITY; LUNG FUNCTION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SMOKING CESSATION; TREATMENT PLANNING;

EID: 0032787864     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1021325     Document Type: Review

References (58)

1. Anthonisen NR, Wright EC, the IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-819
2. Eliasson O, DeGraff AC. Criteria for reversibility and obstruction in bronchodilator trials. Am Rev Respir Dis 1985;132: 858-864
3. Marini JJ, Lakshminarayan S. The effect of atropine inhalation in 'irreversible' chronic bronchitis. Chest 1980;77: 591-596
4. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor WD, Newhouse MT. Bronchodilators in chronic airflow limitation: Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987;135: 1069-1074
5. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289
6. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-821
7. Rennard SI. Extended bronchodilator treatment in chronic obstructive pulmonary disease. European Respiratory Review 1996;6:282-286
8. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, Braman S, Olsen G, Phillips Y ATS statement: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(5 (part 2)):S77-S120
9. 1: The lung health study. JAMA 1994;272:1497-1505
10. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993;328: 1017-1022
11. Jenne JW. Theophylline is no more obsolete than "two puffs qid" of current beta-2 agonists. Chest 1990;98:3-4
12. Barnes PJ. New developments in anticholinergic drugs. European Respiratory Review 1996;6:290-294
13. Gross NJ, Skorodin MS. State of the art. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129: 856-870
14. Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP, Lennard-Jones T, Clarke SW. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986;41:295-300
15. Skorodin MS, Gross NJ, Moritz T, et al. Oxitropium bromide, a new anticholinergic bronchodilator. Ann Allergy 1986;56:229-232
16. Frith PA, Jenner B, Dangerfield RN, Atkinson J, Drennan C. Dose-response and time response study of a new anticholinergic bronchodilator drug. Chest 1986;89:249-253
17. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995;50: 62-66
18. Cazzola M, Matera MG, Di Perna F, Calderaro F, Califano C, Vinciguerra A. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Resp Med 1998;92:354-357
19. Maesen FPV, Smeets JJ, Costongs MAL, Wald FDM, Cornelissen PJG. Ba 679 Br, a new long-acting antimuscarinic bronchodilator, a pilot dose-escalation study. Eur Respir J 1993;6:1031-1036
20. Maesen FPV, Smeets JJ, Sledsens TJM, Wald FDM, Cornelissen PJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-1513
21. Allen CJ, Campbell AH. Dose-response of ipratropium bromide assessed by two methods. Thorax 1979;34:137-139
22. LeDoux EJ, Morris JF, Temple WP, Cuncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989;95:1013-1016
23. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98: 835-839
24. Easton PA, Jadue C, Dhingra S, Antonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide). N Engl J Med 1986;315:753-759
25. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary diseaes, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial. Chest 1994;105:1411-1419
26. Levin DC, Little KS, Lauglin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, McFarland K, Petty TL, Silvers W, Rennard SI, Mueller M, Repsher LH, Zuwallack RL, Vale R. Addition of anticholinergic solution prolongs bronchodilator effect of B2 agonists inpatients with chronic obstructive pulmonary disease. Amer J Med 1996;100(Suppl 1A):1A-40S-48S
27. Blosser SA, Maxwell SL, Reeves-Hoche M, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a B2-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995;108:730-735
28. Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990;11:461-486
29. Kirsten DK, Wegner RE, Forres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1994;104:1101-1107
30. Siafakis NM, Vermeire P, Pride NB, et al. ERS consensus statement: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 9:1398-1420
31. Newhouse MT. Is theophylline obsolete? Chest 1990;98:1-2
32. Niewoehner DE. Theophylline therapy: A continuing dilemma. Chest 1990;98:5
33. Jubran A, Gross N, Ramsdell J, Simonian F, Schuttenhelm K, Sax M, Kaniecki DJ, Goldberg Arnold RJ, Sonnenberg FA. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. Chest 1993;103:678-684
34. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-1094
35. Ferguson G. Respiratory muscle function in chronic obstructive pulmonary disease. Sem Respir Med 1993;14(6): 430-445
36. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. Ann Intern Med 1991;114:216-223
37. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995;108: 1568-1571
38. Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CLA, Akkermans R, Molema J, Folgering H, van Weel C. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: A 4-year prospective study. Ann Intern Med 1993;118:770-778
39. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, Sykes RS, Rennard SI. Aerosolized beclomethasone in chronic bronchitis. Am Rev Respir Dis 1992;146:389-395
40. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate, 750 ug and 1500 ug twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax 1993;48: 309-316
41. Kerstjens HAM, Brand PLP, Hughes MD, Robinson NJ, Postma DS, Slutter HJ, Bleeker ER, Dekhuijzen PNR, De Jong PM, Mengelers HJJ, Overbeek SE, Schoonbrood DFME, Dutch Chronic Non-Specific Lung Disease Study Group. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992;327:1413-1419
42. Robertson AS, Gove RI, Wieland GA, et al. A double-blind comparison of oral prednisolone 40 mg/d with inhaled beclomethasone dipropionate 1500 mg/d in patients with adult onset chronic obstructive airways disease. Eur J Respir Dis 1986;146(suppl):565-569.
43. Weir DC, Gove RI, Robertson AS, et al. Corticosteroid trials in non-asthmatic chronic airflow obstruction: A comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;45:112-117
44. Mendella LA, Manfreda J, Warren CW, Anthonisen NR. Steroid response in stable chronic obstructive pulmonary disease. Ann Intern Med 1982;96:17-21
45. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Hartmut L. Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-1548
46. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, Hernandez C, Rodriguez-Roisin R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-1505
47. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive airways disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:16-20
48. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990;142:1004-1008
49. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
50. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: A metaanalysis. JAMA 1995;273(12):957-960
51. Semmungel TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422
52. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med 1991;90(suppl 6A):87-92S
53. Ball P, Make BJ. Acute exacerbations of chronic bronchitis: An international comparison. Chest 1998;113(suppl) (3): 199S-204S
54. Balter MS, Ryland RH, Low DE, Renzi PM, Braude AC, Cole PJ, Hodder RV, McCombs JS, Allard C, Braldy J, Brown NE, Duguid N, et al. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J 1994;151(10, Supplement):8-23
55. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, Rubin BK. Effects of aerosolized surfactant in patients with stable chronic bronchitis. JAMA 1997;278:1426-1431
56. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting J-W. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease: A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997;156:1800-1806
57. Schols AMW, Soeters PB, Mosteret RM, Pluymers RJ, Frantzen PJ, Wouters EFM. Physiological effects of nutritional support and anabolic steroids in COPD patients. Am J Respir Crit Care Med 1995;152:1268-1274
58. Schols AMW, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-1797